Corcept Therapeutics announced the initiation of its MOMENTUM clinical trial, which is designed to examine the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension. This study represents a strategic expansion of the company's research into the broader impact of cortisol modulation.
The MOMENTUM trial builds upon previous findings, such as those from the CATALYST study, which revealed a high prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. Identifying hypercortisolism in resistant hypertension patients could significantly expand the potential market for Corcept's cortisol-modulating therapies.
Resistant hypertension affects a large patient population, and if a significant portion is found to have underlying hypercortisolism, it could lead to new diagnostic and treatment paradigms. This trial underscores Corcept's commitment to leveraging its cortisol modulation platform across various severe metabolic and endocrinologic disorders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.